IMPORTANCE: Refined knowledge of risk factors for critical influenza and COVID-19 may lead to improved understanding of pathophysiology and better pandemic preparedness.

OBJECTIVES: To compare risk-factor profiles of patients admitted to intensive care with critical influenza and COVID-19.

DESIGN, SETTING, AND PATIENTS: A nationwide retrospective matched case-control study, including all adults admitted to an ICU in Sweden with influenza or COVID-19 between 2014 and September 2020 and a matched control population (ratio 1:5, patients:controls).

MEASUREMENTS AND MAIN RESULTS: Admission to an ICU. The study included 1,873 influenza and 2,567 COVID-19 ICU patients, and 9,365 and 12,835 controls, respectively, matched on sex, age, and geographical region. Influenza patients were older and less likely male, and carried a larger burden of comorbidity and a higher Simplified Acute Physiology Score III score, whereas short-term mortalities were similar when compared to COVID-19 patients. The risk-factor profiles at ICU admission were largely comparable including socioeconomic, psychiatric, and several somatic variables. Hypertension was a strong risk factor in critical COVID-19 patients compared with influenza. Nonglucocorticoid immunosuppressive therapy was associated with critical influenza but not COVID-19. Premorbid medication with statins and renin-angiotensin-aldosterone system inhibitors reduced the risk for both conditions, the opposite was seen for glucocorticoid medication. Notably, medication with betablockers, oral anticoagulation, and platelet inhibitors reduced the risk of critical COVID-19 but not influenza.

CONCLUSIONS: The risk-factor profiles for critical influenza and COVID-19 were largely comparable; however, some important differences were noted. Hypertension was a stronger risk factor for developing critical COVID-19, whereas the use of betablockers, oral anticoagulants, and platelet inhibitors all reduced the risk of ICU admission for COVID-19 but not influenza. Findings possibly reflected differences in pathophysiological mechanisms between these conditions.

KEY WORDS: cohort studies; COVID-19; critical care; follow-up studies; influenza; mortality
influences of comorbidities, medication, and level of education on the risk of admission to an ICU for influenza and COVID-19.

MATERIALS AND METHODS

This study was approved by the Swedish Ethical Review Authority (approval number 2020-02544). The study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines for cohort studies.

Study Design and Population

In Sweden, public healthcare, including intensive care, is tax-funded and available to all citizens and permanent residents. All have a unique personal identity number, making linkage possible between national registers with virtually no loss to follow-up. In this nationwide study, we identified all ICU patients greater than or equal to 18 years old in the Swedish Intensive Care Registry (SIR) who were admitted with influenza between 2014 and 2020 (5). We also identified all ICU patients with COVID-19 admitted from March to September 2020. All influenza and COVID-19 cases were admitted with corresponding codes according to the International Classification of Diseases, 10th Edition (ICD-10), in addition to a polymerase chain reaction test for the viral pathogen in question. Each influenza and COVID-19 patient was matched to five control individuals who were of the same age and sex, and who were registered in the same region at their corresponding time of ICU admission. The control individuals were extracted from the Total Population Register (6).

SIR collects individual patient data within the legal framework of the Swedish National Quality Registries. Written informed consent from each patient is not required, but patients can withdraw their data from the registry at any time. Data in SIR include baseline demographics, comorbidities, variables included in the Simplified Acute Physiology Score (SAPS III), and variables on treatments given within the ICU. Data in SIR are recorded in raw format and transferred electronically to SIR after local validation at the individual ICUs. After central validation at SIR, data entries outside prespecified limits are returned to the specific ICUs for correction before data are added to the master database. Mandatory surveillance data of influenza and COVID-19 are routinely reported in cooperation with the Public Health Agency of Sweden.

Exposures and Outcomes

Baseline characteristics were defined at the time of ICU admission and extracted from SIR. Physiologic variables were recorded within 1 hour on either side of the time of ICU admission. Information on comorbidities was obtained from the Swedish National Patient Register (7). The register includes data on in- and outpatient cares, including ICD-10 codes. Primary care is not included. Comorbidity was assessed up to 5 years prior to ICU admission and was classified in accordance with Charlson comorbidity index (CCI) (8) with the addition of hypertension, psychiatric illness, and substance abuse. We used ICD-10 groups to identify psychiatric illness (F20-F99 and F10-F14) and substance abuse (F16 and F18-F19). Data on pre-ICU medications were extracted from the National Prescribed Drug Registry (9). Data on education were extracted from the Longitudinal Integration Database for Health Insurance and Labour Market Studies (10). Level of education at the time of ICU admission was categorized as less than or equal to 9, 10–12, and greater than 12 years of schooling, respectively, the last category indicating university-level education. Information on mortality was obtained from the Swedish Cause of Death Register (11). All extracted data as specified above were extracted for cases (influenza and COVID-19) and control individuals.

Outcomes

The primary outcome was critical influenza or COVID-19 requiring ICU admission.

Statistical Analysis

Categorical data are presented as proportions and percentages. Continuous data are presented as median with interquartile ranges or mean with sd, where applicable. Associations between potential risk factors and ICU admission were estimated by conditional logistic regression and presented as odds ratios (ORs) with corresponding 95% CIs. The covariates included in the univariate model were decided a priori and were chosen based on results from previous studies and with a potential influence on the risk of critical disease. Covariates with univariate significance were included in the
multivariable models. ORs from the logistic regression models are presented to express the likelihood of being admitted to ICU. Finally, the association between potential risk factors and 30-day mortality was explored using logistic regression. All analyses were carried out for influenza and COVID-19 (and, respectively, matched controls) separately. Data were analyzed as complete cases. A two-sided p value of less than 0.05 was considered statistically significant. Stata/MP 14.2 (StataCorp, College Station, TX) was used for all analyses.

RESULTS

Patient Sampling

Thirty influenza and 30 COVID-19 patients (and their respective controls) were excluded due to invalid registration. Invalid registration refers to patients with a temporary personal identification number, which makes linkages with national health registries impossible. In total, 1,873 influenza patients and 2,567 COVID-19 were included with 9,365 and 12,835 controls, respectively (Fig. 1). Controls were drawn without resampling for the respective disease cohorts. An ICU patient included as a case in the current study could not subsequently be included as a control. However, a control individual could later be included as a case (ICU patient) in the study. In total, 36 patients occurred twice in the dataset.

Patient Characteristics

The influenza patients were older (median age 69 vs 61) with a more balanced sex distribution (54% vs 73% male) compared with COVID-19 patients. The overall comorbidity burden was somewhat higher among influenza patients with a median CCI of 2 compared with 1 for COVID-19. The mean SAPS III score was 61 for influenza and 53 for COVID-19. At 30 days, 24% and 23% had died in the respective cohorts, and at 90 days, 29% and 28% had died (Table 1), respectively. Among influenza patients, 40% were admitted from emergency departments and 49% from general wards. Corresponding figures for COVID-19 patients were 25% and 71%.

Factors Associated With Critical Disease

In the multivariable conditional logistic regression analyses, the risk-factor profiles for critical disease showed great similarities between influenza and COVID-19. Hypertension, arrhythmia, congestive heart failure, hemi/paraplegia, chronic obstructive pulmonary disease (COPD), diabetes, kidney disease, severe liver disease, psychiatric illness,
### TABLE 1.
Demographics, Comorbidities, Premorbid Medication, and Outcomes for ICU-Admitted Influenza and COVID-19 Patients and Controls

| Variable                                      | Influenza |          | COVID-19 |          |
|-----------------------------------------------|-----------|----------|----------|----------|
|                                               | Controls  | Cases    | Controls | Cases    |
|                                               | (n = 9,365) | (n = 1,873) | (n = 12,835) | (n = 2,567) |
| Age (median, IQR)                             | 69 (56–77)  | 69 (56–77)  | 61 (52–69)  | 61 (52–69)  |
| Male sex, n (%)                               | 5060 (54)  | 1,012 (54)  | 9,335 (73)  | 1,867 (73)  |
| Level of education, n (%)                     |            |          |          |          |
| ≤ 9 yr                                        | 2,448 (26)  | 651 (36)   | 2,453 (19)  | 653 (26)    |
| 10–12 yr                                      | 4,047 (44)  | 820 (45)   | 5,720 (45)  | 1,121 (45)  |
| > 12 yr                                       | 2,780 (30)  | 343 (19)   | 4,467 (35)  | 700 (28)    |
| Comorbidity                                   |            |          |          |          |
| Charlson comorbidity index, median (IQR)      | 0 (0–1)    | 2 (1–4)   | 0 (0–1)   | 1 (0–2)    |
| Myocardial infarction, n (%)                  | 461 (4.9)   | 292 (16)   | 451 (3.5)  | 209 (8.1)  |
| Arrhythmia, n (%)                             | 1,009 (11)  | 535 (29)   | 894 (7.0)  | 417 (16)   |
| Congestive heart failure, n (%)               | 452 (4.8)   | 495 (26)   | 376 (2.9)  | 253 (9.9)  |
| Hypertension, n (%)                           | 2,150 (23)  | 943 (50)   | 2,124 (16) | 1,239 (48) |
| Peripheral vascular disease, n (%)            | 268 (2.9)   | 143 (7.6)  | 238 (1.9)  | 93 (3.6)   |
| Cerebrovascular disease, n (%)                | 610 (6.5)   | 274 (15)   | 472 (3.7)  | 219 (8.5)  |
| Hemi/paraplegia, n (%)                        | 115 (1.2)   | 107 (5.7)  | 83 (0.6)   | 98 (3.8)   |
| Chronic obstructive pulmonary disease, n (%)  | 518 (5.5)   | 578 (31)   | 467 (3.6)  | 476 (18)   |
| Rheumatological disease, n (%)                | 399 (4.3)   | 210 (11)   | 390 (3.0)  | 176 (6.9)  |
| Diabetes, n (%)                               |            |          |          |          |
| No                                            | 8,556 (91)  | 1,336 (71)| 11,965 (93)| 1,823 (71)|
| Without complications                         | 560 (6.0)   | 317 (17)   | 599 (4.7)  | 570 (22)   |
| With complications                            | 249 (2.7)   | 220 (12)   | 271 (2.1)  | 174 (6.8)  |
| Kidney disease, n (%)                         |            |          |          |          |
| No                                            | 9,159 (98)  | 1,603 (86)| 12,617 (98)| 2,301 (90)|
| Moderate                                      | 202 (2.2)   | 239 (13)   | 210 (1.6)  | 232 (9.0)  |
| End-stage renal disease                       | 4 (0.0)     | 31 (1.7)   | 8 (0.1)    | 34 (1.3)   |
| Liver disease, n (%)                          |            |          |          |          |
| No                                            | 9,235 (99)  | 1,773 (95)| 12,679 (99)| 2,476 (96)|
| Mild                                          | 101 (1.1)   | 57 (3.0)   | 124 (1.0)  | 57 (2.2)   |
| Moderate/severe                               | 29 (0.3)    | 43 (2.3)   | 32 (0.2)   | 34 (1.3)   |
| Malignancy, n (%)                             | 1,329 (14)  | 357 (19)   | 1,255 (9.8)| 262 (10)   |
| Psychiatric illness, n (%)                   | 695 (7.4)   | 426 (23)   | 919 (7.2)  | 381 (15)   |
| Substance abuse, n (%)                        | 215 (2.3)   | 160 (8.5)  | 316 (2.5)  | 109 (4.2)  |
| Medication                                    |            |          |          |          |
| Nonsteroid immunosuppressive therapy, n (%)   | 191 (2.0)   | 146 (7.8)  | 298 (2.3)  | 118 (4.6)  |
| Statins, n (%)                                | 1,978 (21)  | 566 (30)   | 2,605 (20) | 714 (28)   |

(Continued)
TABLE 1. (Continued).
Demographics, Comorbidities, Premorbid Medication, and Outcomes for ICU-Admitted Influenza and COVID-19 Patients and Controls

| Variable                              | Influenza       | COVID-19        |
|---------------------------------------|-----------------|-----------------|
|                                       | Controls (n = 9,365) | Cases (n = 1,873) | Controls (n = 12,835) | Cases (n = 2,567) |
| Steroids, n (%)                       | 497 (5.3)       | 396 (21)        | 552 (4.3)             | 284 (11)          |
| Renin-angiotensin-aldosterone system inhibitors, n (%) | 2,707 (29) | 713 (38)        | 3,711 (29)            | 940 (37)          |
| Betablockade, n (%)                   | 2,044 (21.8)    | 720 (38)        | 2,137 (17)            | 621 (24)          |
| Oral anticoagulants, n (%)            | 717 (7.7)       | 310 (17)        | 762 (5.9)             | 215 (8.4)         |
| Platelet inhibitors, n (%)            | 1,353 (14)      | 444 (24)        | 1,435 (11)            | 382 (15)          |
| Simplified Acute Physiology Score III, median (IQR) | 61 (53–71) | 53 (47–60)      |
| 30-d mortality, n (%)                 | 21 (0.2)        | 459 (24)        | 20 (0.2)              | 594 (23)          |
| 90-d mortality, n (%)                 | 73 (0.8)        | 544 (29)        | 33 (0.3)              | 689 (28)          |

IQR = interquartile range.

and baseline medication with glucocorticoids were all associated with ICU admission in both diseases. A high level of education and baseline medication with statins as well as renin-angiotensin-aldosterone system (RAAS) inhibitors reduced the risk for critical disease in both cohorts. Substance abuse and nonsteroid immunosuppressive therapy proved to be risk factors for critical influenza but not COVID-19, whereas the opposite was noted for myocardial infarction and rheumatological disease. β-blockers, oral anticoagulants, and platelet inhibitors were associated with a reduced risk of ICU admission due to COVID-19 but not influenza (Tables 2 and 3; Fig. 2; and Supplemental Table 1, http://links.lww.com/CCX/B2).

DISCUSSION

To date, several studies have compared COVID-19 with seasonal influenza from different perspectives (12, 13). To the best of our knowledge, this is the first comparative case-control study of the critical forms of these conditions. In this nationwide study, patients admitted to an ICU in Sweden with influenza were older and less likely to be male, carried a greater burden of comorbidity, and had a higher SAPS III score compared with patients admitted to ICU with COVID-19. Despite this, the short-term mortality was comparable. In the analyses of risk-factor profiles, we noted several similarities that possibly reflect a general vulnerability to severe infection. Notably, premorbid use of RAAS inhibitor and statin medication was associated with a reduced risk of ICU admission for both diseases. Some important differences were observed between the influenza and COVID-19 cohorts. The use of β-blockers, oral anticoagulants, and platelet inhibitors was associated with a reduced risk for critical COVID-19; this association was not seen in influenza.

Some differences in demography were noted. The higher age and burden of comorbidity seen among influenza compared with COVID-19 patients have been reported previously (13, 14). A sex-related difference was noted where almost three-quarters of the COVID-19 patients were male. This difference has also been reported in several studies (3, 4). In Sweden, more females have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than men, but there is a clear male predominance when it comes to critical forms of disease (15). This observation has been suggested to relate to sex-related differences in the RAAS, specifically differences in the expression of angiotensin-converting enzyme 2 (ACE₂), the port of entry for SARS-CoV-2 virus (16).

Influenza patients were older and had a higher CCI and SAPS III score but a comparable short-term mortality. Similar results have been reported previously (12). Cardiovascular disease is a condition known to increase the risk of adverse outcomes in several settings. Hypertension has been shown to be a risk factor for...
### TABLE 2.
Influenza Patients

| Variable                                | Univariate          | Multivariable        |
|-----------------------------------------|---------------------|----------------------|
|                                         | OR (95% CI)         | p                    | OR (95% CI)         | p        |
| **Level of education**                  |                     |                      |                     |          |
| ≤ 9 yr                                  | Ref                 |                      | Ref                 |          |
| 10–12 yr                                | 0.73 (0.65–0.82)    | 0.000                | 0.81 (0.70–0.94)    | 0.006    |
| > 12 yr                                 | 0.43 (0.37–0.50)    | 0.000                | 0.60 (0.50–0.72)    | 0.000    |
| **Comorbidity**                         |                     |                      |                     |          |
| Myocardial infarction                   | 3.8 (3.2–4.5)       | 0.000                | 1.1 (0.91–1.4)      | 0.302    |
| Arrhythmia                              | 4.1 (3.6–4.7)       | 0.000                | 2.0 (1.6–2.5)       | 0.000    |
| Hypertension                            | 4.3 (3.8–4.9)       | 0.000                | 2.1 (1.8–2.5)       | 0.000    |
| Congestive heart failure                | 8.5 (7.2–9.9)       | 0.000                | 3.3 (2.6–4.0)       | 0.000    |
| Peripheral vascular disease             | 2.9 (2.3–3.5)       | 0.000                | 0.91 (0.68–1.2)     | 0.522    |
| Cerebrovascular disease                 | 2.6 (2.2–3.0)       | 0.000                | 1.1 (0.90–1.4)      | 0.334    |
| Hemi/paraplegia                         | 4.9 (3.8–6.5)       | 0.000                | 3.4 (2.4–4.9)       | 0.000    |
| Chronic obstructive pulmonary disease   | 8.0 (6.9–9.2)       | 0.000                | 4.5 (3.8–5.4)       | 0.000    |
| Rheumatological disease                 | 2.9 (2.4–3.5)       | 0.000                | 1.0 (0.78–1.3)      | 0.995    |
| **Diabetes**                            |                     |                      |                     |          |
| No                                      | Ref                 |                      | Ref                 |          |
| Without complications                   | 3.9 (3.3–4.5)       | 0.000                | 2.4 (1.9–2.9)       | 0.000    |
| With complications                      | 6.2 (5.1–7.5)       | 0.000                | 3.0 (2.3–4.0)       | 0.000    |
| **Kidney disease**                      |                     |                      |                     |          |
| No                                      | Ref                 |                      | Ref                 |          |
| Moderate                                | 7.4 (6.0–9.0)       | 0.000                | 2.3 (1.7–2.9)       | 0.000    |
| End-stage renal disease                 | 43 (15–121)         | 0.000                | 7.1 (2.3–22.3)      | 0.001    |
| **Liver disease**                       |                     |                      |                     |          |
| No                                      | Ref                 |                      | Ref                 |          |
| Mild                                    | 2.9 (2.1–4.1)       | 0.000                | 1.3 (0.85–2.1)      | 0.219    |
| Moderate/severe                         | 7.6 (4.7–12)        | 0.000                | 3.1 (1.6–5.8)       | 0.000    |
| Malignancy                              | 1.5 (1.3–1.7)       | 0.000                | 1.0 (0.88–1.3)      | 0.599    |
| Psychiatric illness                     | 3.8 (3.3–4.3)       | 0.000                | 2.4 (2.0–2.9)       | 0.000    |
| Substance abuse                         | 4.1 (3.3–5.0)       | 0.000                | 1.8 (1.4–2.4)       | 0.000    |
| **Medication**                          |                     |                      |                     |          |
| Nonsteroid immunosuppressive therapy    | 4.2 (3.3–5.2)       | 0.000                | 2.5 (1.8–3.5)       | 0.000    |
| Statins                                 | 1.7 (1.5–1.9)       | 0.000                | 0.74 (0.62–0.89)    | 0.002    |
| Steroids                                | 5.0 (4.3–5.8)       | 0.000                | 2.3 (1.9–2.8)       | 0.000    |
| Renin-angiotensin-aldosterone system inhibitors | 1.6 (1.4–1.8)  | 0.000                | 0.69 (0.58–0.81)    | 0.000    |
| Betablockade                            | 2.5 (2.3–2.9)       | 0.000                | 0.98 (0.82–1.2)     | 0.783    |
| Oral anticoagulants                     | 2.7 (2.3–3.1)       | 0.000                | 1.0 (0.78–1.29)     | 0.959    |
| Platelet inhibitors                     | 2.0 (1.7–2.3)       | 0.000                | 1.2 (0.97–1.5)      | 0.088    |

OR = odds ratio, Ref = reference.
Univariate and multivariable logistic regression, associations with ICU admission and presented as odds ratios.
### TABLE 3.
COVID-19 Patients

| Variable                                      | Univariate |          |          | Multivariable |          |          |
|-----------------------------------------------|------------|----------|----------|---------------|----------|----------|
|                                               | OR (95% CI)| p        | OR (95% CI)| p             |          |          |
| Level of education                            |            |          |          |                |          |          |
| ≤ 9 yr                                        | Ref        |          | Ref      |                |          |          |
| 10–12 yr                                      | 0.81 (0.70–0.94) | 0.006    | 0.75 (0.66–0.86) | 0.000    |          |          |
| > 12 yr                                       | 0.60 (0.50–0.72) | 0.000    | 0.70 (0.61–0.81) | 0.000    |          |          |
| Comorbidity                                   |            |          |          |                |          |          |
| Myocardial infarction                         | 1.1 (0.91–1.4) | 0.302    | 1.3 (1.1–1.7) | 0.018    |          |          |
| Arrhythmia                                    | 2.0 (1.6–2.5) | 0.000    | 2.0 (1.7–2.5) | 0.000    |          |          |
| Hypertension                                  | 2.1 (1.8–2.5) | 0.000    | 4.8 (4.2–5.6) | 0.000    |          |          |
| Congestive heart failure                      | 3.3 (2.6–4.0) | 0.000    | 1.5 (1.2–2.0) | 0.001    |          |          |
| Peripheral vascular disease                   | 0.91 (0.68–1.2) | 0.522    | 0.94 (0.69–1.3) | 0.695    |          |          |
| Cerebrovascular disease                       | 1.1 (0.90–1.4) | 0.334    | 1.1 (0.90–1.4) | 0.279    |          |          |
| Hemi/paraplegia                               | 3.4 (2.4–4.9) | 0.000    | 3.4 (2.3–5.0) | 0.000    |          |          |
| Chronic obstructive pulmonary disease         | 4.5 (3.8–5.4) | 0.000    | 4.4 (3.7–5.2) | 0.000    |          |          |
| Rheumatological disease                       | 1.0 (0.78–1.3) | 0.995    | 1.4 (1.1–1.8) | 0.009    |          |          |
| Diabetes                                      |            |          |          |                |          |          |
| No                                            | Ref        |          | Ref      |                |          |          |
| Without complications                         | 2.4 (1.9–2.9) | 0.000    | 4.5 (3.8–5.3) | 0.000    |          |          |
| With complications                            | 3.0 (2.3–4.0) | 0.000    | 2.1 (1.6–2.8) | 0.000    |          |          |
| Kidney disease                                |            |          |          |                |          |          |
| No                                            | Ref        |          | Ref      |                |          |          |
| Moderate                                      | 2.3 (1.7–2.9) | 0.000    | 2.9 (2.2–3.7) | 0.000    |          |          |
| End-stage renal disease                       | 7.1 (2.3–22.3) | 0.001    | 10.7 (4.0–28.7) | 0.000    |          |          |
| Liver disease                                 |            |          |          |                |          |          |
| No                                            | Ref        |          | Ref      |                |          |          |
| Mild                                          | 1.3 (0.85–2.1) | 0.219    | 0.86 (0.56–1.3) | 0.477    |          |          |
| Moderate/severe                               | 3.1 (1.6–5.8) | 0.000    | 1.9 (1.0–3.5) | 0.036    |          |          |
| Malignancy                                    | 1.0 (0.88–1.3) | 0.599    |          |                |          |          |
| Psychiatric illness                           | 2.4 (2.0–2.9) | 0.000    | 1.7 (1.4–1.9) | 0.000    |          |          |
| Substance abuse                               | 1.8 (1.4–2.4) | 0.000    | 0.86 (0.65–1.1) | 0.280    |          |          |
| Medication                                    |            |          |          |                |          |          |
| Nonsteroid immunosuppressive therapy          | 2.5 (1.8–3.5) | 0.000    | 1.2 (0.86–1.6) | 0.334    |          |          |
| Statins                                       | 0.74 (0.62–0.89) | 0.002    | 0.74 (0.63–0.86) | 0.000    |          |          |
| Steroids                                      | 2.3 (1.9–2.8) | 0.000    | 1.5 (1.2–1.8) | 0.000    |          |          |
| Renin-angiotensin-aldosterone system inhibitors | 0.69 (0.58–0.81) | 0.000    | 0.58 (0.50–0.67) | 0.000    |          |          |
| Betablockade                                  | 0.98 (0.82–1.2) | 0.783    | 0.76 (0.64–0.89) | 0.001    |          |          |
| Oral anticoagulants                           | 1.0 (0.78–1.29) | 0.959    | 0.50 (0.39–0.65) | 0.000    |          |          |
| Platelet inhibitors                           | 1.2 (0.97–1.5) | 0.088    | 0.72 (0.59–0.88) | 0.002    |          |          |

OR = odds ratio, Ref = reference.

Univariate and multivariable logistic regression, associations with ICU admission and presented as odds ratios.
Severe forms of COVID-19 (4, 17). In line with these findings, hypertension proved to be associated with COVID-19 and, to a lesser extent, with influenza in the current study. Hypertension has previously been reported as a risk factor also related to other coronaviruses such as SARS and Middle East respiratory syndrome (18). The explanatory mechanisms behind these observations are not fully elucidated, but it has been suggested that this may be related to RAAS and possibly altered expression of ACE2 (19). Congestive heart failure has been shown to increase the risk of ICU admission in community-acquired sepsis (20). This was also seen with influenza and, to a lesser degree, COVID-19 in this study. COPD proved to be a strong risk factor related to both conditions, in keeping with previous reports (21, 22).

Rheumatological disease and immunosuppressive therapy are to some extent related entities. We found that the former increased the risk of critical COVID-19 but not influenza, whereas the opposite was noted for nonglucocorticoid immunosuppressive therapy. In line with our study, a recent meta-analysis reported that the risk of developing COVID-19 was not significantly higher among immunosuppressed patients compared with the general community (23). No data on the outcomes of patients contracting COVID-19 were reported in this study. Moreover, a report from the COVID-19 Global Rheumatology Alliance showed that patients with rheumatological diseases treated with glucocorticoids had a higher risk of hospitalization for COVID-19, whereas patients on anticytokine treatment had a lower risk (24).

Severe COVID-19 has been advocated as a hyperinflammatory condition, and anticytokine treatment is currently used for selected cases in the ICU. It might be that preemptive anticytokine treatment reduces the risk of severe COVID-19. As previously shown (21), immunosuppression increased the risk of critical influenza in this study. This condition involves a secondary bacterial
infection in up to 30% of the cases (25), a complication expected to increase with a reduced immune defense. Preadmission glucocorticoid medication increased the risk of contracting either condition. This has previously been reported for both influenza (26) and COVID-19 (24, 27). Interestingly, in-hospital treatment with glucocorticoids in influenza-induced acute respiratory distress syndrome (ARDS) has been shown to increase mortality (28), whereas it is has been shown to decrease mortality in critical COVID-19 (29). This discrepancy may have to do with hyperinflammation in the latter and a relatively high presence of secondary bacterial infections in the former.

Diabetes is commonly reported as a risk factor for both COVID-19 (12) and influenza (30), as well as sepsis (20). Glucose variability has been associated with severity of influenza (31) in experimental models, and it has been proposed that diabetes causes a functional immune deficiency reducing immune cell function (32). An increased expression of ACE2 patients with type 2 diabetes has been suggested as a mechanism for the development of severe COVID-19, as these receptors in the lungs and other tissues have been shown to play a role in infection with SARS-CoV-2 (33). These findings are in keeping with the current study, where diabetes was a significant risk factor for both conditions. End-stage renal disease, comprising a small group of patients, proved to be the strongest risk factor for ICU admission for both conditions. This notion is well-recognized in the literature (34, 35). Severe liver disease is a serious condition with a reduced life expectancy and is associated with immune deficiency. In line with our findings, severe liver disease has previously been reported to be associated with a several-fold increase in mortality in both COVID-19 (36) and influenza (37). Malignancy was not associated with ICU admission for influenza or COVID-19 in our study. Cancer has been reported to be associated with an increased risk of influenza complications (38), whereas the findings for COVID-19 are less consistent. In line with our finding, a matched cohort study (39) from New York reported no association between cancer and severe outcomes from COVID-19, whereas a Chinese study (40) reported an increased risk. A possible admission bias for patients with advanced malignancy cannot be fully ruled out in our study.

Socioeconomic status and psychiatric illness are reported to be associated with adverse outcomes in numerous medical conditions (20), including our study. Substance abuse proved to be a risk factor for influenza but not for COVID-19. This finding is not consistent with previous reports where substance abuse disorders are reported as risk factors for severe infections (20) including COVID-19 (41).

Statins have been advocated as potentially beneficial to critical illness due to their anti-inflammatory properties. However, recent studies do not support the use of statins in sepsis (42) or ARDS (43). Notably, these drugs may exhibit antiviral effects, and in line with the findings of the current study, premorbid statin use has been shown to reduce the risk of critical disease in both influenza (44) and COVID-19 (45).

During the initial phase of the COVID-19 pandemic, potential harm from RAAS inhibitors was discussed as these drugs may increase the expression of angiotensin-converting enzyme receptors, a port of entry for the SARS-CoV-2 virus. With increased knowledge of the role of the RAAS system in the pathophysiology of COVID-19, RAAS inhibitors were later advocated as potentially beneficial (46) and suggested as a line of treatment. A recent South American Randomized Controlled Trial (RCT) (47) showed improved survival from telmisartan treatment in hospitalized COVID-19 patients, whereas no effect was seen from losartan treatment in an American study (48). In keeping with our findings, baseline use of RAAS inhibitors has been associated with a reduced risk of adverse outcomes in both influenza (49) and COVID-19 (46).

Use of β-blockers was associated with a reduced risk of critical COVID-19 but not influenza in our study. Premorbid use of β-blockers has been associated with improved outcomes in sepsis (50), and recently, a small randomized study showed that in-hospital treatment with metoprolol improved gas exchange in COVID-19–induced ARDS (51).

A hallmark of critical COVID-19 is thrombogenicity, in particular pulmonary embolism, that has been reported to occur in a third of ICU patients (52). These are typically located in the segmental arteries as well as the microcirculation and possibly generated in situ rather than embolized. Furthermore, the occurrence rate has been shown to be approximately three-fold higher in ICU-admitted COVID-19 patients compared with influenza and ICU patients in general (53). Premorbid use of oral anticoagulants was associated with a reduction in the risk of critical COVID-19 but not influenza in our study. With some exceptions (54), this association has not been noted for COVID-19 in previous studies (27, 55, 56), and a recent RCT failed to show
any protective effects from oral anticoagulation initiated in stable outpatients with symptomatic COVID-19 (57). Antiplatelet therapy may have beneficial effects in severe COVID-19 through several mechanisms including inhibition of platelet aggregation, reduction of platelet-derived inflammation, blocking thrombogenic neutrophil extracellular traps, and reducing disseminated intravascular coagulation. Low-dose aspirin has been used as a line of therapy, and several observational studies have reported that aspirin is associated with a reduced risk of adverse outcome in COVID-19 (58, 59). In line with oral anticoagulants, premorbid treatment with platelet inhibitors was associated with a reduction in the risk of contracting critical COVID-19 but not influenza in our study. Recently, a large RCT failed to show any effect on 28-day survival but reported a significantly shorter period to discharge in aspirin-treated hospitalized COVID-19 patients (60).

Our study suggests that several preexisting medical conditions known to increase the general risk of critical illness also increase the risk for the two studied conditions. Hypertension proved to be a strong risk factor for critical COVID-19, possibly suggesting involvement of the RAAS in the pathophysiology. Likewise, premorbid RAAS inhibition was associated with a lower risk of critical disease due to COVID-19. This latter association was also seen for critical influenza. The significant risk reduction seen in patients with anticoagulant and platelet inhibitor medication in COVID-19 but not influenza suggests that thromboembolism is an important component in the development of critical forms of the former viral disease.

As with all registry-based studies, this study has limitations. The COVID-19 patients were sampled during the first pandemic wave, and the results may not be generalizable to later waves. Despite a certain preparedness and a rapid increase in ICU beds following initial reports from Italy and China, ICU capacity was obviously strained during the first wave of the pandemic. Thus, a possible admission bias between the two cohorts cannot be fully ruled out. Whether or not the pandemic affected thresholds for ICU admission has been a subject of debate and previous studies are few. Variations in ICU threshold in terms of age and comorbidities could theoretically affect the results, but unfortunately, the data set does not allow analyses of that question. In addition, data on ICU staffing and hospital care given before ICU admission would have added value. Data on ethnic or racial diversity among the study population were not available. During the pandemic, there has been a rapid increase in knowledge of optimal treatment of COVID-19. Clinical management algorithms are constantly evolving including early treatment measures to prevent disease progression. For example, inpatient treatment with dexamethasone or low-molecular-weight heparins preceding or during intensive care are not included in SIR. COVID-19 vaccines were not yet available during the inclusion period, and data on vaccination status for influenza patients are not available in the current study.

Strengths of the study include the use of validated national quality and health registers with a low rate of missing data and minimal loss to follow-up (Supplemental Table 2, http://links.lww.com/CCX/B3). Data are prospectively reported to SIR for quality-surveillance purposes and are, therefore, unbiased in relation to this study. All influenza and COVID-19 ICU patients in Sweden are included in the study, providing high generalizability to similar healthcare systems.

CONCLUSIONS

In this nationwide case-control study, we compared the pattern of risk factors for contracting critical influenza and COVID-19. Similarities were noted in that several significant preexisting medical conditions commonly reported as risk factors associated with critical illness proved to be risk factors also in these two conditions. Premorbid use of both statins and RAAS inhibitors was associated with a reduced risk of contracting critical forms of both conditions, whereas β-blockers, oral anticoagulants, and platelet inhibitors only reduced the risk of critical COVID-19. The latter findings possibly reflect an important role of thromboembolism in the pathophysiology of critical COVID-19.

ACKNOWLEDGMENTS

We thank the participating ICUs for their hard work in contributing data to the Swedish Intensive Care Registry.

1 Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.
2 Section of Anesthesiology and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
3 Department of Anesthesia and Intensive Care, Uppsala University Hospital, Uppsala, Sweden.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccejournal).

Supported, in part, by grants from the SciLifeLab National COVID-19 Research Program, financed by the Knut and Alice Wallenberg Foundation and the Stockholm County Council.

Dr. Oldner is currently receiving a grant from European Society of Intensive Care Medicine and The Swedish Carnegie Hero Funds, and funds from Karolinska Institutet and through the regional agreement on medical and clinical research between Stockholm County Council and Karolinska Institutet. Dr. Larsson is currently receiving a grant from the Swedish Society of Medicine and the Stockholm County Council. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Address requests for reprints to: Emma Larsson, MD, PhD, Perioperative Medicine and Intensive Care, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. E-mail: emma.ca.larsson@regionstockholm.se

No sponsor had any role in design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the article; or decision to submit the article for publication.

REFERENCES

1. WHO: https://www.who.int/news/item/13-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year. Accessed April 20, 2022

2. Center for Systems Science and Engineering at Johns Hopkins University: Covid-19 Dashboard. Available at: https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd-40299423467b48e9ecf6. Accessed April 20, 2022

3. Larsson E, Brattström O, Agvald-Öhman C, et al; Karolinska Intensive Care COVID-19 Study Group: Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary hospital in Stockholm, Sweden. Acta Anaesthesiol Scand 2021; 65:76–81

4. Richardson S, Hirsch JS, Narasimhan M, et al: Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020;323:2052–2059

5. Svenska Intensivvårdsregistret (SIR). Available at: www.icuregno.org.

6. Statistics Sweden: Total Population Register. Available at: https://www.registerforskning.se/en/register/population-statistics/

7. National Board of Health and Welfare: Swedish National Patient Register. Available at: https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/patientregistret/

8. Quan H, Li B, Couris CM, et al: Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173:676–682

9. National Board of Health and Welfare: National Prescribed Drug Register. 2022. Available at: https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-prescribed-drug-register/

10. Statistics Sweden: Longitudinal Integrated Database for Health Insurance and Labour Market Studies (LISA). Available at: https://www.scb.se/en/services/guidance-for-researchers-and-universities/vilka-mikrodata-finns/longitudinella-register/longitudinal-integrated-database-for-health-insurance-and-labour-market-studies-lisa/

11. National Board of Health and Welfare: Cause of Death Register. 2022. Available at: https://www.socialstyrelsen.se/statistik-och-data/register/alla-register/dodsorsaksregistret/. Accessed April 20, 2022

12. Piroth L, Cottenet J, Mariet AS, et al: Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: A nationwide, population-based retrospective cohort study. Lancet Respir Med 2021; 9:251–259

13. Donnino MW, Moskowitz A, Thompson GS, et al: Comparison between patients hospitalized with influenza and COVID-19 at a tertiary care center. J Gen Intern Med 2021; 36:1689–1695

14. Brehm TT, van der Meirsch M, Hennigs A, et al: Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Sci Rep 2021; 11:5803

15. Public Health Agency of Sweden: 2022. Available at: https://www.tolkhalsomyndigheten.se/the-public-health-agency-of-sweden/. Accessed April 20, 2022

16. Bwire GM: Coronavirus: Why men are more vulnerable to covid-19 than women? SN Compr Clin Med 2020; 2:874–876

17. Larsson E, Brattström O, Agvald-Öhman C, et al; Karolinska Intensive Care COVID-19 Study Group: Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary hospital in Stockholm, Sweden. Acta Anaesthesiol Scand 2021; 65:76–81

18. Clark CE, McDonagh STJ, McManus RJ, et al: COVID-19 and hypertension: Risks and management. A scientific statement on behalf of the British and Irish Hypertension Society. J Hum Hypertens 2021; 35:304–307

19. Savoia C, Volpe M, Kreutz R: Hypertension, a moving target in COVID-19: Current views and perspectives. Circ Res 2021; 128:1062–1079

20. Lindström AC, Eriksson M, Mårtensson J, et al: Nationwide case-control study of risk factors and outcomes for community-acquired sepsis. Sci Rep 2021; 11:15118

21. Martínez A, Soldevila N, Romero-Tamarit A, et al: Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group: Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype. PLoS One 2019; 14:e0210353

22. Gerayeli FY, Milne S, Cheung C, et al: COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClincalMedicine 2021; 33:100789

23. Tassone D, Thompson A, Connell W, et al: Immunosuppression as a risk factor for COVID-19: A meta-analysis. Intern Med J 2021; 51:199–205

24. Gianfrancesco M, Hyrich KL, Al-Adely S, et al; COVID-19 Global Rheumatology Alliance: Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020; 79:859–866

25. Sarda C, Palma P, Rello J: Severe influenza: Overview in critically ill patients. Curr Opin Crit Care 2019; 25:449–457

26. Tinsley A, Navabi S, Williams ED, et al: Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis 2019; 25:369–376
27. Bergman J, Ballin M, Nordström A, et al: Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: A nationwide study. *Eur J Epidemiol* 2021; 36:287–298

28. Zhang Y, Sun W, Svendsen ER, et al: Do corticosteroids reduce the mortality of influenza A (H1N1) infection? A meta-analysis. *Crit Care* 2015; 19:46

29. The-RECOVERY-Collaborative-Group: Dexamethasone in hospitalized patients with COVID-19 — preliminary report. *N Engl J Med* 2020; 384:693–704.

30. Goiejienbier M, van Sloten TT, Slobbe L, et al: Benefits of flu vaccination for persons with diabetes mellitus: A review. *Vaccine* 2017; 35:5095–5101.

31. Marshall RJ, Armut P, Hulme KD, et al: Glycemic variability in diabetes increases the severity of influenza. *mBio* 2020; 11:e02841–e02819.

32. Frydrych LM, Fattahi F, He K, et al: Diabetes and sepsis: Risk, recurrence, and ruination. *Front Endocrinol (Lausanne)* 2017; 8:271.

33. Rajpal A, Rahimi L, Ismail-Beigi F: Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. *J Diabetes* 2020; 12:895–908.

34. Bowman BT, Rosner MH: Influenza and the patient with end-stage renal disease. *J Nephrol* 2018; 31:225–230.

35. Henry BM, Lippi G: Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *Int Urol Nephrol* 2020; 52:1193–1194.

36. Gao YD, Ding M, Dong X, et al: Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy* 2021; 76:428–455.

37. Härmälä S, Parisinos CA, Shallcross L, et al: Effectiveness of influenza vaccines in adults with chronic liver disease: A systematic review and meta-analysis. *BMJ Open* 2019; 9:e031070.

38. Bitterman R, Eliakim-Raz N, Vinograd I, et al: Influenza vaccination for persons with diabetes mellitus: A review. *Vaccine* 2017; 35:5095–5101.

39. Brar G, Pinheiro LC, Shusterman M, et al: COVID-19 severity and outcomes in patients with cancer: A matched cohort study. *J Clin Oncol* 2020; 38:3914–3924.

40. Dai M, Liu D, Liu M, et al: Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. *Cancer Discov* 2020; 10:783–791.

41. Baillargeon J, Polychronopoulou E, Kuo YF, et al: The impact of substance use disorder on COVID-19 outcomes. *Psychiatr Serv* 2021; 72:578–581.

42. Thomas G, Hraiech S, Loundou A, et al: Statin therapy in critically-ill patients with severe sepsis: A review and meta-analysis of randomized clinical trials. *Minerva Anestesiol* 2015; 81:921–930.

43. Papazian L, Roch A, Charles PE, et al; STATIN-VAP Study Group: Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: A randomized clinical trial. *JAMA* 2013; 310:1692–1700.

44. Atamna A, Babitch T, Bracha M, et al: Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza. *Eur J Clin Microbiol Infect Dis* 2019; 38:2341–2348.

45. Bergqvist R, Ahlqvist VH, Lundberg M, et al: HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study. *PLoS Med* 2021; 18:e1003820.

46. Zhang P, Zhu L, Cai J, et al: Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. *Circ Res* 2020; 126:1671–1681.

47. Duarte M, Pelorosso F, Nicolosi LN, et al: Telmisartan for treatment of COVID-19 patients: An open multicenter randomized clinical trial. *EClinicalMedicine* 2021; 37:100962.

48. Puskarich MA, Ingraham NE, Merck LH, et al: Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial. *medRxiv Preprint* posted online August 28, 2021. doi: https://doi.org/10.1101/2021.08.25.21262623.

49. Chung SC, Providencia R, Sofat R: Association between angiotensin blockade and incidence of influenza in the United Kingdom. *N Engl J Med* 2020; 383:397–400.

50. Tan K, Harazim M, Simpson A, et al: Association between premorbid beta-blocker exposure and sepsis outcomes-the beta-blockers in European and Australian/American Septic Patients (BEAST) study. *Crit Care Med* 2021; 49:1493–1503.

51. Clemente-Moragón A, Martínez-Milla J, Oliver E, et al: Metoprolol in critically ill patients with COVID-19. *J Am Coll Cardiol* 2021; 78:1001–1011.

52. Klok FA, Kruip M, van der Meer NJM, et al: Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020; 191:145–147.

53. Poissy J, Goutay J, Caplan M, et al; Lille ICU Haemostasis Investigators: Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: The ACTIV-4B randomized clinical trial. *Circulation* 2020; 142:184–186.

54. Chocron R, Galand V, Cellier J, et al: Anticoagulation before hospitalization is a potential protective factor for COVID-19: Insight from a French multicenter cohort study. *J Am Heart Assoc* 2021; 10:e018624.

55. Tremblay D, van Gerwen M, Alsen M, et al: Impact of anticoagulation prior to COVID-19 infection: A propensity score-matched cohort study. *Blood* 2020; 136:144–147.

56. Flam B, Wintzell V, Ludvigsson JF, et al: Direct oral anticoagulant use and risk of severe COVID-19. *J Intern Med* 2021; 289:411–419.

57. Connors JM, Brooks MM, Scibura FC, et al; ACTIV-4B Investigators: Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: The ACTIV-4B randomized clinical trial. *JAMA* 2021; 326:1703–1712.

58. Osborne TF, Veigulis ZP, Arreola DM, et al: Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. *PLoS One* 2021; 16:e0246825.

59. Chow JH, Khanna AK, Kethireddy S, et al: Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. *Anesth Analg* 2021; 132:930–941.

60. Abani O, Abbas A, Abbas F, et al: Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. *Lancet* 2022; 399:143–151.